Articles

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

Department of Translational Oncology, Genentech, Inc., South San Francisco, CA, USA;
Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;
Division of Hematology and Oncology, University of California at San Francisco, San Francisco, USA;
Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;
Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;
Division of Hematology and Oncology, University of California at San Francisco, San Francisco, USA;
Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA;
Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA;
Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA;
Helen Diller Comprehensive Cancer Center, University of California at San Francisco, USA
Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;
Department of Translational Oncology, Genentech, Inc., South San Francisco, CA, USA;
Department of Translational Oncology, Genentech, Inc., South San Francisco, CA, USA;
Haematologica Early view May 15, 2020 https://doi.org/10.3324/haematol.2019.244020